How much did Takara Bio achieve in EBIT for the current year?
In the current year, Takara Bio has achieved an EBIT of 3 B JPY.
Takara Bio EBIT 2024
Takara Bio EBIT
3 B JPY
Ticker
4974.T
ISIN
JP3460200003
WKN
A0DNGL
In 2024, Takara Bio's EBIT was 3 B JPY, a -85.38% increase from the 20.54 B JPY EBIT recorded in the previous year.
The Takara Bio EBIT history
| YEAR | EBIT (undefined JPY) |
|---|---|
| 2027e | - |
| 2026e | - |
| 2025e | - |
| 2024 | 3 |
| 2023 | 20.54 |
| 2022 | 28.9 |
| 2021 | 13.95 |
| 2020 | 6.27 |
| 2019 | 5.46 |
| 2018 | 3.56 |
| 2017 | 3.2 |
| 2016 | 2.67 |
| 2015 | 2.3 |
| 2014 | 1.95 |
| 2013 | 1.69 |
| 2012 | 1.55 |
| 2011 | 1.1 |
| 2010 | 0.56 |
| 2009 | 0.37 |
| 2008 | 0.53 |
| 2007 | -0.21 |
| 2006 | -1.48 |
| 2005 | -1.08 |
Takara Bio Revenue, EBIT, Net Income JP3460200003 · A0DNGL
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Takara Bio, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Takara Bio from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Takara Bio’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Takara Bio. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Takara Bio’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Takara Bio’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Takara Bio’s growth potential.
Takara Bio Revenue, EBIT and net profit per share
| Date | Takara Bio Revenue | Takara Bio EBIT | Takara Bio Net Income |
|---|---|---|---|
| 2027e | 55.53 B undefined | 0 undefined | 5.3 B undefined |
| 2026e | 51.91 B undefined | 0 undefined | 4.37 B undefined |
| 2025e | 48.26 B undefined | 0 undefined | 3.69 B undefined |
| 2024 | 43.51 B undefined | 3 B undefined | 1.48 B undefined |
| 2023 | 78.14 B undefined | 20.54 B undefined | 16.01 B undefined |
| 2022 | 67.7 B undefined | 28.9 B undefined | 19.85 B undefined |
| 2021 | 46.09 B undefined | 13.95 B undefined | 9.55 B undefined |
| 2020 | 34.57 B undefined | 6.27 B undefined | 3.82 B undefined |
| 2019 | 35.84 B undefined | 5.46 B undefined | 3.66 B undefined |
| 2018 | 32.31 B undefined | 3.56 B undefined | 2.34 B undefined |
| 2017 | 29.38 B undefined | 3.2 B undefined | 1.35 B undefined |
| 2016 | 29.73 B undefined | 2.67 B undefined | 1.33 B undefined |
| 2015 | 25.97 B undefined | 2.3 B undefined | 963 M undefined |
| 2014 | 23.91 B undefined | 1.95 B undefined | 1.47 B undefined |
| 2013 | 20.56 B undefined | 1.69 B undefined | 1.46 B undefined |
| 2012 | 19.58 B undefined | 1.55 B undefined | 1.02 B undefined |
| 2011 | 18.74 B undefined | 1.1 B undefined | 605 M undefined |
| 2010 | 19.33 B undefined | 557 M undefined | 591 M undefined |
| 2009 | 18.91 B undefined | 365 M undefined | 642 M undefined |
| 2008 | 20.28 B undefined | 532 M undefined | 679 M undefined |
| 2007 | 20.98 B undefined | -211 M undefined | 320 M undefined |
| 2006 | 16.53 B undefined | -1.48 B undefined | -1.06 B undefined |
| 2005 | 13.69 B undefined | -1.08 B undefined | -1.28 B undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2005 | 13.69 B JPY | -1.08 B JPY | -1.28 B JPY |
| 2006 | 16.53 B JPY | -1.48 B JPY | -1.06 B JPY |
| 2007 | 20.98 B JPY | -211 M JPY | 320 M JPY |
| 2008 | 20.28 B JPY | 532 M JPY | 679 M JPY |
| 2009 | 18.91 B JPY | 365 M JPY | 642 M JPY |
| 2010 | 19.33 B JPY | 557 M JPY | 591 M JPY |
| 2011 | 18.74 B JPY | 1.1 B JPY | 605 M JPY |
| 2012 | 19.58 B JPY | 1.55 B JPY | 1.02 B JPY |
| 2013 | 20.56 B JPY | 1.69 B JPY | 1.46 B JPY |
| 2014 | 23.91 B JPY | 1.95 B JPY | 1.47 B JPY |
| 2015 | 25.97 B JPY | 2.3 B JPY | 963 M JPY |
| 2016 | 29.73 B JPY | 2.67 B JPY | 1.33 B JPY |
| 2017 | 29.38 B JPY | 3.2 B JPY | 1.35 B JPY |
| 2018 | 32.31 B JPY | 3.56 B JPY | 2.34 B JPY |
| 2019 | 35.84 B JPY | 5.46 B JPY | 3.66 B JPY |
| 2020 | 34.57 B JPY | 6.27 B JPY | 3.82 B JPY |
| 2021 | 46.09 B JPY | 13.95 B JPY | 9.55 B JPY |
| 2022 | 67.7 B JPY | 28.9 B JPY | 19.85 B JPY |
| 2023 | 78.14 B JPY | 20.54 B JPY | 16.01 B JPY |
| 2024 | 43.51 B JPY | 3 B JPY | 1.48 B JPY |
| 2025e | 48.26 B JPY | 0 JPY | 3.69 B JPY |
| 2026e | 51.91 B JPY | 0 JPY | 4.37 B JPY |
| 2027e | 55.53 B JPY | 0 JPY | 5.3 B JPY |
Takara Bio stock margins JP3460200003 · A0DNGL
The Takara Bio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Takara Bio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Takara Bio.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Takara Bio's sales revenue. A higher gross margin percentage indicates that the Takara Bio retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Takara Bio's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Takara Bio's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Takara Bio's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Takara Bio. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Takara Bio's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Takara Bio Margin History
| Takara Bio Gross margin | Takara Bio Profit margin | Takara Bio EBIT margin | Takara Bio Profit margin |
|---|---|---|---|
| 2027e | 61.85 % | 0 % | 9.54 % |
| 2026e | 61.85 % | 0 % | 8.42 % |
| 2025e | 61.85 % | 0 % | 7.64 % |
| 2024 | 61.85 % | 6.9 % | 3.4 % |
| 2023 | 57.29 % | 26.29 % | 20.49 % |
| 2022 | 72.69 % | 42.69 % | 29.32 % |
| 2021 | 69.16 % | 30.27 % | 20.72 % |
| 2020 | 61.06 % | 18.15 % | 11.05 % |
| 2019 | 57.72 % | 15.24 % | 10.2 % |
| 2018 | 57.73 % | 11 % | 7.23 % |
| 2017 | 57.71 % | 10.9 % | 4.6 % |
| 2016 | 54.91 % | 8.97 % | 4.49 % |
| 2015 | 53.24 % | 8.86 % | 3.71 % |
| 2014 | 52.6 % | 8.17 % | 6.15 % |
| 2013 | 53.61 % | 8.22 % | 7.11 % |
| 2012 | 53.04 % | 7.9 % | 5.23 % |
| 2011 | 52.72 % | 5.88 % | 3.23 % |
| 2010 | 51.95 % | 2.88 % | 3.06 % |
| 2009 | 52.22 % | 1.93 % | 3.39 % |
| 2008 | 50.26 % | 2.62 % | 3.35 % |
| 2007 | 46.81 % | -1.01 % | 1.53 % |
| 2006 | 43.3 % | -8.97 % | -6.4 % |
| 2005 | 46.53 % | -7.92 % | -9.37 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2005 | 46.53 % | -7.92 % | -9.37 % |
| 2006 | 43.3 % | -8.97 % | -6.4 % |
| 2007 | 46.81 % | -1.01 % | 1.53 % |
| 2008 | 50.26 % | 2.62 % | 3.35 % |
| 2009 | 52.22 % | 1.93 % | 3.39 % |
| 2010 | 51.95 % | 2.88 % | 3.06 % |
| 2011 | 52.72 % | 5.88 % | 3.23 % |
| 2012 | 53.04 % | 7.9 % | 5.23 % |
| 2013 | 53.61 % | 8.22 % | 7.11 % |
| 2014 | 52.6 % | 8.17 % | 6.15 % |
| 2015 | 53.24 % | 8.86 % | 3.71 % |
| 2016 | 54.91 % | 8.97 % | 4.49 % |
| 2017 | 57.71 % | 10.9 % | 4.6 % |
| 2018 | 57.73 % | 11 % | 7.23 % |
| 2019 | 57.72 % | 15.24 % | 10.2 % |
| 2020 | 61.06 % | 18.15 % | 11.05 % |
| 2021 | 69.16 % | 30.27 % | 20.72 % |
| 2022 | 72.69 % | 42.69 % | 29.32 % |
| 2023 | 57.29 % | 26.29 % | 20.49 % |
| 2024 | 61.85 % | 6.9 % | 3.4 % |
| 2025e | 61.85 % | 0 % | 7.64 % |
| 2026e | 61.85 % | 0 % | 8.42 % |
| 2027e | 61.85 % | 0 % | 9.54 % |
Takara Bio Aktienanalyse
What does Takara Bio do?
Takara Bio Inc is a Japanese biotechnology company that has been active in the medical and life science industry since its founding in 1967. The company is a strong player in the field of molecular biology and operates in several countries such as the USA, Europe, and Asia. Takara Bio Inc was established as an independent company in 1999, focusing exclusively on the production of molecular biology products. The company offers a wide range of products in the fields of research and diagnostics, including enzymes, PCR kits, vectors and plasmids, antibodies, proteins, and cell culture products. Takara Bio Inc is organized into two divisions: Life Science Research and Diagnostics. The Life Science Research division provides products and solutions for research and development in areas such as molecular biology, neuroscience, proteomics, and genomics. The Diagnostics division offers products and solutions for clinical diagnostics and drug development. Takara Bio Inc also specializes in the automation of molecular biology procedures and offers automated systems that can perform processes such as nucleic acid extraction, PCR, and sequencing. The company is committed to sustainability and environmental protection, adhering to strict environmental and quality standards in its production processes and implementing waste reduction and efficient resource utilization programs. Overall, Takara Bio Inc is a leading company in the field of molecular biology, offering a wide range of products and solutions for research and diagnostics, and has become a key player in the life science industry through its global expansion and ability to provide custom solutions. Takara Bio ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Takara Bio's EBIT
Takara Bio's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Takara Bio's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Takara Bio's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Takara Bio’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Takara Bio stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Takara Bio.
How has the EBIT of Takara Bio developed in recent years?
The EBIT of Takara Bio has increased by -85.38% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Takara Bio?
The EBIT of Takara Bio is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Takara Bio pay?
Over the past 12 months, Takara Bio paid a dividend of 17 JPY . This corresponds to a dividend yield of about 1.64 %. For the coming 12 months, Takara Bio is expected to pay a dividend of 19.79 JPY.
What is the dividend yield of Takara Bio?
The current dividend yield of Takara Bio is 1.64 %.
When does Takara Bio pay dividends?
Takara Bio pays a quarterly dividend. This is distributed in the months of April, April, April, April.
How secure is the dividend of Takara Bio?
Takara Bio paid dividends every year for the past 16 years.
What is the dividend of Takara Bio?
For the upcoming 12 months, dividends amounting to 19.79 JPY are expected. This corresponds to a dividend yield of 1.9 %.
In which sector is Takara Bio located?
Takara Bio is assigned to the 'Health' sector.
Wann musste ich die Aktien von Takara Bio kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Takara Bio from 6/1/2024 amounting to 17 JPY, you needed to have the stock in your portfolio before the ex-date on 3/28/2024.
When did Takara Bio pay the last dividend?
The last dividend was paid out on 6/1/2024.
What was the dividend of Takara Bio in the year 2023?
In the year 2023, Takara Bio distributed 42 JPY as dividends.
In which currency does Takara Bio pay out the dividend?
The dividends of Takara Bio are distributed in JPY.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Takara Bio
Our stock analysis for Takara Bio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Takara Bio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
